Pharma & Biotech Patent Litigation USA & Canada

The Forum on Pharma & Biotech Patent Litigation USA & Canada is organized by American Conference Institute (ACI) and C5 Group. For more than 40 years, ACI and C5 have brought together business leaders, legal professionals and international experts for conferences focused on timely business intelligence, networking and professional development.

ACI’s 2nd Annual Forum on Pharma & Biotech Patent Litigation USA & Canada is a three-day program focused on the legal, procedural, regulatory, and strategic issues shaping life sciences patent disputes across the United States and Canada, with a dedicated third day addressing European developments and cross-border implications.

The conference will take place October 14–16, 2026, at 3 Times Square, 3 Times Sq, New York, NY 10036.

The program is designed for in-house counsel and executives from pharmaceutical and biotechnology companies, including heads of patent or IP litigation, vice presidents of intellectual property, IP and patent counsel, heads of legal or legal affairs, heads of global IP or patent strategy, innovation and portfolio leaders, R&D patent managers, and licensing and commercialization professionals. It is also relevant to law firm attorneys practicing in life sciences intellectual property, patent law, and patent litigation.

The conference primarily brings together professionals from pharmaceutical, biotechnology, and broader life sciences organizations. The program also includes law firms, litigation and economic consulting organizations, litigation finance and IP-focused organizations, academic and policy institutions, and members of the judiciary.

Key topics include Hatch-Waxman and BPCIA litigation, skinny labeling after Hikma v. Amarin, §112 written description and enablement, obviousness-type double patenting, forum selection across district courts, the PTAB and ITC, Canadian PM(NOC) practice, discovery and dispositive motions, experts and jury strategy, GLP-1 and emerging-technology disputes, AI ethics, trade secrets, damages and settlements, UPC developments, and cross-border patent strategy.

Attendees will examine how current case law, regulatory policy, agency activity, and litigation trends are changing pharma and biotech patent strategy in the United States and Canada. The program also provides practical guidance on selecting forums, handling discovery and motions, using experts effectively, protecting trade secrets, addressing AI-related professional responsibilities, coordinating cross-border litigation, and preparing for European developments that may affect North American patent portfolios.

The faculty includes senior in-house IP and patent litigation counsel, experienced life sciences patent litigators from private practice, members of the federal judiciary, policy and association representatives, academics, and industry consultants.

The 2026 faculty represents pharmaceutical and biotechnology companies including Novo Nordisk, 10x Genomics, Merck Sharp & Dohme LLC, Sanofi, Eisai, Theravance Biopharma, Ferring Pharmaceuticals, CSL Behring, Bausch Health Companies, Ascendis, and Memorial Sloan Kettering Cancer Center. The faculty also includes the United States District Court for the District of New Jersey and the District of Delaware, Pharmaceutical Research and Manufacturers of America, Unified Patents, The University of Akron, the University of Richmond School of Law, and a broad group of U.S., Canadian, and European law firms.

The agenda includes breakfast and registration periods, morning and afternoon breaks, networking over lunch, concurrent breakout sessions, roundtable-style discussions, and multi-speaker panels.

Yes. Group discounts are available for registrations from the same organization or firm when participants register together in one transaction. Groups of 4–8 receive a 10% conference discount, groups of 9–12 receive a 15% discount, and groups of 12 or more should call 888-224-2480.

The conference is covered by the Worry-Free Registration Guarantee policy. Registrants who register and pay are eligible for a full refund until September 30. If unable to attend, they may choose either a full credit note for themselves or a colleague to attend another event, or a full refund. All cancellations and changes must be submitted to the Customer Experience Team by September 30.

ACI has arranged a limited number of rooms at a negotiated rate at the Hilton New York Times Square, 234 W 42nd St, New York, NY 10036. Guests can contact the hotel directly and quote “ACI / Pharma Biotech Conference”; the room block cut-off date is September 15, 2026, and availability or the negotiated rate cannot be guaranteed after the cut-off or once the block is full.

CLE accreditation will be sought in those jurisdictions requested by the registrants which have continuing education requirements. This course is identified as non-transitional for the purposes of CLE accreditation.